5 Stocks to Watch: Week of 9/28/2026
Here's a head start on your stock research for next week... Our top 5, high-potential stock picks for the week of 9/28.
- Bristol Myers Squibb (NYSE: BMY): Our latest Trade of the Week
- Riskified (RSKD): #1 in its industry with excellent growth prospects
- Betterware De Mexico (BWMX): 79% upside on continental expansion plans
- Crescent Energy (CRGY): Permian synergies powering a 81% upside call
- Warrior Met Coal (HCC): Premium coal miner with 39% upside target
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1- Bristol Myers Squibb (NYSE: BMY)
One of the world’s largest pharma companies just earned our Editor-in-Chief’s Trade of the Week designation. With an 18.9% profit margin, a 45.1% return on equity, and fresh late-stage pipeline wins, the company is executing a portfolio renewal that analysts are increasingly willing to underwrite.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $61.55 — get current quote
Max 1-year forecast: $82.00
Why we're watching:
- BMY has broad, bullish coverage among the analysts we track, with 7 Strong Buy and 5 Hold recommendations. See all recommendations here
- For example, Piper Sandler researcher David Amsellem (a top 4% rated analyst) recently reiterated his Strong Buy recommendation with a price target suggesting the stock could see greater than 30% upside in the coming year.
- Our own Editor-in-Chief, Steve Reitmeister, is even more bullish on the stock. He named it as his Trade of the Week in our most recent WallStreetZen Live webinar … If you want to get our next pick before the crowd, join our next no-paywall event this coming Monday. Sign up here.
- Pipeline catalyst: BMY announced positive topline results from a recent Phase 2 trial related to cell therapy, with the blood cancer program meeting its main goal in mid-stage testing.
- Industry ranking context: BMY is currently the #1 highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
- Zen Ratings highlights: BMY earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: BMY excels for Value and Sentiment with A grades, reflecting a P/E of under 14 against an industry average near 40 alongside strengthening analyst conviction, while maintaining solid Bs for Momentum, Safety, Financials, and Artificial Intelligence — a six-grade strength profile that positions it as one of the better-rounded large-cap pharma setups available. See all 7 Component Grades here
2- Warrior Met Coal (NYSE: HCC)
Warrior Met Coal produces premium metallurgical coal for the global steel industry. With a 17.2% profit margin and strengthening coal fundamentals, the company is well-positioned to capitalize on sustained demand from international steelmakers.
Zen Rating: B (Buy) — see full analysis
Recent Price: $88.95 — get current quote
Max 1-year forecast: $123.00
Why we're watching:
- HCC has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy and 1 Hold recommendations. See all recommendations here
- For example, B. Riley Securities researcher Nick Giles (a top 16% rated analyst) maintained his Strong Buy recommendation with a price target suggesting the stock has roughly 40% upside potential from current levels. Giles cited "modestly higher" Blue Creek output assumptions for the price target hike.
- Industry ranking context: HCC is currently the #1 highest-rated stock in the Coking Coal industry, which has an Industry Rating of D.
- Zen Ratings highlights: HCC earns an overall B rating, equal to a Buy recommendation. This tier represents stocks that have historically delivered nearly 20% annual returns, soundly beating the S&P.
- Component Grades: HCC maintains solid Bs for Financials, Growth, and Value, reflecting the company's disciplined capital allocation and stable cash generation. See all 7 Component Grades here
A note from our sponsors...
Trump Just Changed 401(k) Rules Forever
Your 401(k) may be about to change in a way most Americans haven't heard about.
President Trump's Executive Order #14330 is pushing a major shift in how retirement plans can invest – and it has now reached the Department of Labor for approval.
Get the full story and see how your retirement could be impacted.
3- Betterware De Mexico (NYSE: BWMX)
This “Tupperware south of the border” company is positioning itself for continental expansion with strategic board appointments and innovation initiatives, while analysts see substantial upside based on exceptional revenue projections and market positioning.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $16.45 — get current quote
Max 1-year forecast: $30.00
Why we're watching:
- BWMX has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
- For example, SMALL CAP CONSUMER RESEARCH researcher Eric M Beder (a top 7% rated analyst) recently reiterated his Strong Buy recommendation with a price target implying the stock could see roughly 80% upside in the coming year.
- Industry ranking context: BWMX is currently the #1 highest-rated stock in the Retail industry, which has an Industry Rating of C.
- Zen Ratings highlights: BWMX earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks with this rating have historically beaten the S&P annually.
- Component Grades: BWMX maintains strong Bs for Growth and Value, reflecting both the company's expansion trajectory in the Mexican direct-to-consumer market and attractive valuation metrics, positioning it well for investors seeking exposure to Latin American retail with compelling risk-reward characteristics. See all 7 Component Grades here
4- Crescent Energy (NYSE: CRGY)
Crescent Energy is an oil and gas exploration and production company with assets in proven U.S. basins including Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. The company is expanding free cash flow through Permian synergies and has raised its 2026 outlook, with analysts highlighting strong operational performance improvements and future valuation potential.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $13.42 — get current quote
Max 1-year forecast: $24.00
Why we're watching:
- CRGY has solid, bullish coverage among the analysts we track, with 8 Strong Buy, 1 Buy, and 1 Hold recommendations. See all recommendations here
- For example, Raymond James researcher John Freeman (a top 2% rated analyst) recently maintained his Strong Buy recommendation with a price target roughly 52% above current levels.
- Even more exciting, Wells Fargo researcher Sam Margolin (a top 8% rated analyst) maintained his Strong Buy with a price target roughly 85% above current levels.
- Industry ranking context: CRGY is currently the #6 highest-rated stock in the Oil and Gas industry, which has an Industry Rating of A.
- Zen Ratings highlights: CRGY earns an overall A rating, which amounts to a Strong Buy recommendation. This tier represents the top 5% of stocks tracked based on a careful 115-factor fundamental analysis.
- Component Grades: CRGY shines with an A for Growth, reflecting robust expansion potential driven by Permian synergies and improved operational efficiency, while maintaining solid Bs for Momentum and Value, a combination that positions it attractively for investors seeking energy sector exposure with upside potential. See all 7 Component Grades here
5- Riskified (NYSE: RSKD)
This e-commerce risk management company is capitalizing on the surge in complex fraud patterns driving merchant demand for its unified platform, which delivered its strongest revenue growth in over four years.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $7.86 — get current quote
Max 1-year forecast: $7.50
Why we're watching:
- RSKD has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy and 2 Hold recommendations. See all recommendations here
- For example, DA Davidson researcher Clark Wright (a top 15% rated analyst) recently maintained his Strong Buy rating with a price target suggesting the stock could see greater than 5% upside in the coming year.
- Perhaps more telling, it was recently chosen as our Editor-in-Chief’s Stock of the Week, where Steve Reitmeister calls it one of the best “low-priced tech stocks with high upside potential.” See his full commentary here.
- Q2 earnings demonstrated execution strength: EPS of $0.02 missed estimates by 3.33% with 0% year-over-year growth, while revenue of $98.69M exceeded expectations by 12.15% with 22% YoY growth.
- Industry ranking context: RSKD is currently the #1 highest-rated stock in the App industry, which has an Industry Rating of B.
- Zen Ratings highlights: RSKD earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: RSKD shines with an A for Growth, reflecting accelerating revenue momentum and merchant adoption of its fraud prevention platform, while maintaining solid Bs for Financials, Momentum, and Sentiment, positioning it for continued expansion in the e-commerce security space. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.